Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Copyright 2023 – Finance News Network
Source: Finance News Network
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More13 May 2024 - Lithium Universe's CEO Alex Hanly unveils the company's strides in 2024 towards North American lithium independence.
Read More13 Feb 2020 - Centuria Capital Group (ASX:CNI) Joint CEO, John McBain talks 1H20 results & outlook, including the contribution from recent acquisitions as group AUM now exceeds $7.3B.
Read More27 Nov 2020 - East 33 Limited (ASX:E33) Co-founder and Executive Chairman James Garton talks about the company's dominant position as a supplier and distributor of Sydney Rock Oysters, ambitions ahead of its listing on the ASX and the potential of the world-class Sydney Rock Oyster as a luxury food alongside French Champagne or Beluga Caviar.
Read More30 Sep 2020 - Nuheara Limited (ASX:NUH) Managing Director & CEO Justin Miller provides an update on the company's range of innovative audio wearables, changes in its marketing and distribution as a result of COVID19, financial position and outlook.
Read More06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
Read More03 Apr 2024 - BIFOX's journey from integrated mining to specialty fertilizer production and its plans for IPO as CEO Tim Koster shares insights on strategy and market growth.
Read More01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell therapy platform from Imperial College London.
Read More10 June 2020 - Lepidico Limited (ASX:LPD) Managing Director, Joe Walsh provides an update on the company's plans to transition its Phase 1 Project to development following the recent completion of a Definitive Feasibility Study for the redevelopment of two mines in Namibia and a chemical conversion plant in Abu Dhabi that employs Lepidico’s proprietary process technologies.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More
